Dr. David R. Knop is the Executive Director of Process Development at Applied Genetic Technologies Corporation (AGTC). He has been responsible for the comprehensive CMC activities of rAAV & rHSV vector development encompassing cell vial to drug product, including CMC support for seven IND-enabling human clinical viral gene therapy candidates, while managing process development, analytical development, tech transfer and external GMP manufacturing, facilities and IT. He has executed technology transfer to contract manufacturing organizations, as well as academic and corporate partners. Dr. Knop has authored numerous manuscripts, presentations, and posters encompassing the production, processing, and purification of rHSV and rAAV vectors for use in gene therapy applications. Previously, Dr. Knop developed biocatalytic routes to high-value pharmaceutical intermediates employed in the syntheses of anti-viral compounds, which resulted in multiple issued and licensed patents.